Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ae2c7cb1e6f8edf1d3dfe246d8ad21b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2316-96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4737 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-248 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
filingDate |
2013-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be9ed6b50136a708ff59184938b5521b |
publicationDate |
2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9701747-B2 |
titleOfInvention |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
abstract |
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10471143-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10344086-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10391169-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10227404-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10858424-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10640560-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10800841-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10787511-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10759853-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10913794-B2 |
priorityDate |
2007-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |